http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011102577-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62cdf93e177ed622f32b4bcae5d87ce3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a787113046bb53243a08d5fdeaaa803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb3778659a9f1a80b32cff21306b6639 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-37 |
| filingDate | 2010-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9f3677820cda0d5bb4b6058bf31ffd8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee6a6019f20b1a2d7f65741f0fc5c385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73559fac41a9d596b5e564b2c35ec0a8 |
| publicationDate | 2011-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2011102577-A1 |
| titleOfInvention | Novel use for scopolin and derivatives thereof |
| abstract | The present invention relates to a novel use for the compound of Chemical formula 1 in order to produce drugs or foods for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like, and to a composition for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like which contains the compound of Chemical formula 1 as an active ingredient, and also to a method for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like comprising the administration of the compound of Chemical formula 1 to a mammal in a therapeutically effective dose. According to the present invention, the compound of Chemical formula 1 has been confirmed to suppress the differentiation of adipocytes, to reduce body weight and the amount of visceral fat, to reduce concentrations of cholesterol, triglycerides, free fatty acids and glucose which are associated with fatty liver and diabetes and the like and to reduce the fatty component in liver tissue, to suppress gene expression associated with obesity in visceral fatty tissue, and to increase the amount of expression of UCP1 and UCP3 which are UCP (uncoupling protein) genes involved in thermogenesis. The compound of Chemical formula 1 can be used to advantage in order to prevent or treat obesity, fatty liver, diabetes, metabolic syndrome and the like since, unlike the obesity treating agents based on synthetic drugs currently in use, it is based on a natural substance and hence entails a very low risk of side effects and, additionally, it exhibits its pharmacological effects by regulating the expression of genes associated with obesity rather than exhibiting pharmacological effects by acting on enzymes or the nervous system. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102617674-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102617674-B |
| priorityDate | 2010-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.